SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today its subsidiary SynX signed five new European distributors for its point-of-care products. The additional distribution agreements significantly increase SynX's coverage to 28 European nations. All of SynX's European distributors were selected based on prior experience in the point-of-care medical device and equipment sector, as well as knowledge with cardiac and central nervous system diseases. Each partner will be responsible for the distribution and marketing of SynX's point-of-care tests and research oriented products for congestive heart failure (CHF) and myocardial infarction. Expected to be commercially available in 2005, the CHF diagnostic product will measure NT-proBNP (N-terminal pro-hormone brain natriuretic peptide), a sensitive and specific biomarker for the diagnosis of congestive heart failure. "These new distribution partners complement our existing distributor networks and provide us with significant relationships with point-of-care diagnostic decision makers in the hospital and research market segments," said Howard C. Birndorf, Nanogen's chairman of the board and chief executive officer. "Development of our congestive heart failure test is progressing and expansion of our distribution network is a key objective that will be important to the success of the product." The newly expanded network provides SynX with exposure to a potential customer base of over 7,500 hospitals, 4,000 clinical laboratories and almost 11,000 cardiac specialists as measured by the European Diagnostic Manufacturers Association, excluding the newly emerging EU nations. About Nanogen, Inc. Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com. Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.